Nyström A, Kiritopoulos D, Ullmark G, et al. - In this randomized, double-blind, placebo-controlled phase two trial, researchers ascertained if denosumab could inhibit early periprosthetic bone loss after total hip arthroplasty (THA) and assessed the impacts on periprosthetic [¹⁸F] standardized uptake values (SUVs). Participants in the study were 64 individuals, aged 35 to 65 years, with unilateral osteoarthritis of the hip. Study participants had surgery with an uncemented THA and were randomized to either two subcutaneous doses of denosumab (n = 32) or placebo (n = 32) given 1-3 days and 6 months after surgery. Findings suggested that denosumab effectively prevents early periprosthetic bone loss after uncemented THA, but the effect declines after treatment have been discontinued. More research is required to decide whether this bone loss would prove clinically significant and, if so, whether either prolonged denosumab therapy or additional antiresorptive therapy can sustain the positive effect seen in this investigation.